Arecor Therapeutics

Arecor is a revenue-generating clinical-stage drug developer. Its proprietary Arestat formulation platforms are the basis of an in-house and partnered pipeline of enhanced products with lower development risks and less onerous regulatory approvals.

View More

Acquisition of Tetris Pharma and £6m equity raise

Arecor Therapeutics | Lighthouse | 01 August 2022

View More

AT278 hits the sweet spot

Arecor Therapeutics | Update | 31 May 2022

View More

Ambitious, focussed, and delivering on its promise

Arecor Therapeutics | Update | 25 April 2022

View More

Formulation expertise exemplified in diabetes

Arecor Therapeutics | Update | 20 January 2021

View More

H121 results underline quality of management execution

Arecor Therapeutics | Lighthouse | 23 September 2021

View More

AT278 Phase I delivers better than expected results

Arecor Therapeutics | Lighthouse | 20 September 2021

View More

Formulating the recipe for success

Arecor Therapeutics | Initiation | 14 September 2021

View More